# ALK21-003: Study of Medisorb® Naltrexone (VIVITROL®) in Alcohol-Dependent Adults

> **NCT01218958** · PHASE3 · COMPLETED · sponsor: **Alkermes, Inc.** · enrollment: 624 (actual)

## Conditions studied

- Alcoholism

## Interventions

- **DRUG:** Medisorb naltrexone 190 mg
- **DRUG:** Medisorb naltrexone 380 mg
- **DRUG:** Placebo matching Medisorb naltrexone 190 mg
- **DRUG:** Placebo matching Medisorb naltrexone 380 mg

## Key facts

- **NCT ID:** NCT01218958
- **Lead sponsor:** Alkermes, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-02
- **Primary completion:** 2003-09
- **Final completion:** 2003-09
- **Target enrollment:** 624 (ACTUAL)
- **Last updated:** 2017-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01218958

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01218958, "ALK21-003: Study of Medisorb® Naltrexone (VIVITROL®) in Alcohol-Dependent Adults". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01218958. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*